Sanofi-Synthelabo Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the month of September 2003, with the report dated September 5, 2003. The registrant is a French private issuer headquartered in Paris. The filing primarily serves to distribute a press release containing financial data prepared under French GAAP.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it defines the methodology for calculating non-GAAP indicators used in the associated press release:
- Reported Sales: Historical sales figures under French GAAP.
- Comparable Sales: Adjusted figures excluding exchange rate fluctuations and changes in Group structure (acquisitions, divestitures, and consolidation percentage changes).
- Developed Sales: Consolidated sales excluding sales to alliance partners but including sales made through alliances not in consolidated sales (specifically citing partnerships with Bristol-Myers Squibb, Fujisawa, and Organon for products like Plavix, Aprovel, Stilnox, and Arixtra).
Material Changes
The provided text does not disclose specific material changes in financial performance versus prior periods. It outlines the framework for analyzing sales changes by isolating the impacts of currency and structural changes.
Guidance, Outlook, and Risks
The filing text does not include forward-looking guidance, management commentary on future outlook, specific risk factors, or contingencies. It focuses on defining the metrics used to demonstrate product market trends.
Investor Verification Checklist
- Verify the full text of the referenced press release to obtain actual revenue and profit figures, as this filing only defines the metrics.
- Confirm the specific exchange rates used to calculate "Comparable Sales" for the period.
- Review the details of alliance sales (Plavix, Aprovel, Stilnox, Arixtra) to understand the composition of "Developed Sales."
- Check subsequent filings for the reconciliation of French GAAP figures to IFRS or US GAAP if required for comparative analysis.